Naturalendo Tech내츄럴엔도텍

Naturalendo Tech still posts operating losses on roughly flat revenue, and its shares have fallen about 11% over the past month.

Naturalendo Tech sells natural-ingredient health foods and cosmeceuticals and develops microneedle patches through its subsidiary Endoderma. On trailing twelve-month figures to H1 2026 it had revenue of about ₩22.8B, an operating loss of about ₩1.8B and free cash flow of about -₩4.4B, with borrowings of ₩7.5B against cash of ₩0.3B. The stock closed at ₩2,125 on 2026-10-20, well below its 52-week high of ₩4,100 but up 17.4% over three months.

What stands out

• Revenue has been broadly flat for two years, at about ₩22.2B in 2025 and ₩22.3B in 2024, after strong growth in 2023.
• Losses have narrowed: the operating margin improved from -14.8% in 2025 to -7.8% on trailing twelve-month figures to H1 2026, though the company is still loss-making.
• Free cash flow is strongly negative at about -₩4.4B against borrowings of ₩7.5B, and the data does not show how this is being funded.
• The company pays no dividend and the P/E ratio is not meaningful because earnings are negative; the P/B ratio is 2.8 and the P/S ratio is 3.0.
• Foreign ownership is small at 1.2%, down slightly from 1.3% sixty days earlier, and recent 20-day investor flows show retail net selling of about ₩87M.

What to watch

• The next periodic filings, since the H1 2026 half-year report was amended in August 2026 and the data does not give a date for the next results.
• Whether losses continue to narrow and whether free cash flow and borrowings are addressed in upcoming filings.
• Recent news coverage is absent from the data, so no company-specific news developments are available to check against.